Comparison between DEXMEDITOMIDINE and KETAMINE premedication intranasaly for intravenous access in children
Not yet recruiting
- Conditions
- Other symptoms and signs involvingthe nervous and musculoskeletal systems, (2) ICD-10 Condition: O||Medical and Surgical, (3) ICD-10 Condition: O||Medical and Surgical, (4) ICD-10 Condition: O||Medical and Surgical,
- Registration Number
- CTRI/2021/11/037896
- Lead Sponsor
- DrAnilin Joeyself
- Brief Summary
It is a randomised,prospective,comparative,double blinded observational study wherein intranasal DEXMEDITOMIDINE and Ketamine are compared to facilitate the intravenous access in children.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
1.Age between 3 months to 5 years 2.ASA grade 1 &2&3 3.Weight of the patient being in normal range for that age and sex.
Exclusion Criteria
- 1)Patients with ASA physical status IV or more.
-
- Patients with any neurological and psychiatric disorders.
-
- History of allergy to any of the drugs being used under study.
-
- Unwilling patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of intranasal DEXMEDITOMIDINE to facilitate the intravenous access in children Sedation score: | Grade1-10minute-separation from mother | Grade2- 10-20minutes-Awake but separated easily | Grade3-20-30minutes-Difficult to separate easily
- Secondary Outcome Measures
Name Time Method Efficacy of intranasal KETAMINE to facilitate the intravenous access in children Sedation score:
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which intranasal Dexmedetomidine and Ketamine modulate the sympathetic nervous system in pediatric patients to facilitate intravenous access?
How does the efficacy of intranasal Dexmedetomidine compare to standard-of-care premedication agents like Midazolam for intravenous access in children with musculoskeletal conditions?
What biomarkers could predict differential response to intranasal Ketamine versus Dexmedetomidine in pediatric patients requiring IV access?
What are the potential adverse events associated with intranasal administration of Dexmedetomidine and Ketamine in children, and how do they compare to intravenous routes?
How do intranasal premedication strategies with Dexmedetomidine and Ketamine compare to other dissociative anesthetics in pediatric procedural sedation?
Trial Locations
- Locations (1)
Hi tech OT complex,5thfloor,deptof anaesthesia,Dr.Dy Patil medical college
🇮🇳Pune, MAHARASHTRA, India
Hi tech OT complex,5thfloor,deptof anaesthesia,Dr.Dy Patil medical college🇮🇳Pune, MAHARASHTRA, IndiaDrAnilin joeyPrincipal investigator9751221626anilinjoey@yahoo.com